U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H20N2O3
Molecular Weight 324.3737
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BINDARIT

SMILES

CC(C)(OCC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3)C(O)=O

InChI

InChIKey=MTHORRSSURHQPZ-UHFFFAOYSA-N
InChI=1S/C19H20N2O3/c1-19(2,18(22)23)24-13-16-15-10-6-7-11-17(15)21(20-16)12-14-8-4-3-5-9-14/h3-11H,12-13H2,1-2H3,(H,22,23)

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15691869

Bindarit (2-Methyl-2-[[1-(phenylmethyl)-1H-indazol-3yl]methoxy]propanoic acid; AF-2838) is an indazolic derivative that is devoid of any immunosuppressive effects and has no effect on arachidonic acid metabolism. It has been proved to have anti-inflammatory activity in a number of experimental diseases, including pancreatitis, arthritis, and lupus nephritis. This therapeutic effect has been associated with its ability to interfere selectively with monocyte recruitment, although the underlying molecular mechanisms are unknown. Bindarit selectively inhibits the production of the monocyte chemotactic protein subfamily of CC inflammatory chemokines (MCP-1/CCL2, MCP-3/CCL7, MCP-2/CCL8) without affecting the production of the cytokines IL-1, IL-6, or the chemokines IL-8, MIP-1α.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P80075
Gene ID: 6355.0
Gene Symbol: CCL8
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
50 μg/mL
25 mg/kg single, oral
dose: 25 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
BINDARIT plasma
Sus scrofa
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10 h
25 mg/kg single, oral
dose: 25 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
BINDARIT plasma
Sus scrofa
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
600 mg 2 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources: Page: p.370
unhealthy, ADULT
n = 11
Health Status: unhealthy
Condition: lupus nephritis
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 11
Sources: Page: p.370
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Treatment with bindarit, a blocker of MCP-1 synthesis, protects mice against acute pancreatitis.
2005 Jun
The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice.
2009 Dec 1
Patents

Sample Use Guides

2x300 mg bid (two times a day); duration:12 weeks
Route of Administration: Oral
Acini were preincubated with/without bindarit (460 μM) for 30 min, and further incubated with caerulein (10−12-10−7 M) for 30 min. The dose of bindarit was chosen based on earlier reports in which it was shown to inhibit MCP-1 synthesis. Bindarit has been shown to preferentially inhibit MCP-1 production in vitro in monocytes without affecting the production of the cytokines IL-1, IL-6, or the chemokines IL-8, protein macrophage inflammatory-1alpha.
Name Type Language
BINDARIT
INN   USAN  
INN   USAN  
Official Name English
BINDARIT [USAN]
Common Name English
AF-2838
Code English
PROPANOIC ACID, 2-METHYL-2-((1-(PHENYLMETHYL)-1H-INDAZOL-3-YL)METHOXY)-
Common Name English
bindarit [INN]
Common Name English
AF 2838
Code English
Classification Tree Code System Code
NCI_THESAURUS C29634
Created by admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
FDA ORPHAN DRUG 110097
Created by admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
Code System Code Type Description
EVMPD
SUB05834MIG
Created by admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
PRIMARY
SMS_ID
100000085886
Created by admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
PRIMARY
INN
6689
Created by admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
PRIMARY
DRUG BANK
DB12739
Created by admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
PRIMARY
PUBCHEM
71354
Created by admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
PRIMARY
FDA UNII
JQ11LH711M
Created by admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
PRIMARY
EPA CompTox
DTXSID30156660
Created by admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
PRIMARY
CAS
130641-38-2
Created by admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
PRIMARY
ChEMBL
CHEMBL2107549
Created by admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
PRIMARY
NCI_THESAURUS
C96701
Created by admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
PRIMARY
USAN
EE-27
Created by admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
PRIMARY